Methods Table 1. Summary of the Process and Methods for the Guidance Development
|Statement of Need||Increased awareness of the rising number of complications of hepatitis C virus (HCV) infection, the recent screening initiatives by the Centers for Disease Control and Prevention (CDC) and US Preventive Services Task Force (USPSTF), and the rapid evolution of highly effective antiviral therapy for HCV infection have driven a need for timely guidance on how new developments change practice for health care professionals.|
|Goal of the Guidance||The goal of the Guidance is to provide up-to-date recommendations to health care practitioners on the optimal screening, management, and treatment for adults with HCV infection in the United States, considering the best available evidence. The Guidance is updated regularly, as new data, information, and tools and treatments become available.|
|Panel members||Panel members are chosen based on their expertise in the diagnosis, management, and treatment of HCV infection. Members from the fields of hepatology and infectious diseases are included, as well as HCV community representatives. Members were appointed by the respective Sponsor Societies after vetting by an appointed Sponsor Society committee. The Panel chairs are appointed by the Society boards, 2 each from the Sponsor Societies. All Panel chairs and members serve as volunteers (not compensated) for defined terms (2-3 years), which may be renewed based on panel needs.|
|Conflict of interest management||The panel was established with the goal of having no personal (ie, direct payment to the individual) financial conflicts of interest among its chairs and among fewer than half of its panel members. All potential panel members are asked to disclose any personal relationship with a pharmaceutical, biotechnology, medical device, or health-related company or venture that may result in financial benefit. Disclosures are obtained prior to the panel member appointments and for 1 year prior to the initiation of their work on the panel. Full transparency of potential financial conflicts is an important goal for the guidance that best ensures the credibility of the process and the recommendations.
Individuals are also asked to disclose funding of HCV-related research activities to their institutional division, department, or practice group.
Disclosures are reviewed by the HCV Guidance Chairs, who make assessments based on the conflict-of-interest policies of the sponsoring organizations (AASLD and IDSA). Personal and institutional financial relationships with commercial entities that have products in the field of hepatitis C are assessed.
The following relationships are prohibited during membership on the guidance panel and are grounds for exclusion from the panel:
The following relationships or activities are reportable but were not deemed to merit exclusion:
The HCV Guidance Chairs achieved a majority of panel members with no personal financial interests.
Panel members are asked to inform the group of any changes to their disclosure status and are given the opportunity to recuse themselves (or be recused) from the discussion where a perceived conflict of interest that cannot be resolved exists.
Financial disclosures for each Panel member can be accessed here.
|Intended Audience||Medical practitioners especially those who provide care to or manage patients with hepatitis C.|
|Sponsors, funding, and collaborating partner||The American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) are the sponsors of the Guidance and provide ongoing financial support.
Grant support was sought and obtained from the Centers for Disease Control and Prevention (CDC) for the initial gathering and review of evidence related to hepatitis C screening and testing recommendations and interventions to implement HCV screening in clinical settings.
|Evidence identification and collection||The Guidance is developed using an evidence-based review of information that is largely available to health care practitioners. Data from the following sources are considered by Panel members when making recommendations: research published in the peer-reviewed literature or presented at major national or international scientific conferences; safety warnings from the US Food and Drug Administration (FDA) or other regulatory agencies or from manufacturers; drug interaction data; prescribing information from FDA-approved products; and registration data for new products under FDA review. Press releases, unpublished reports, and personal communications are generally not considered.
Literature searches are conducted regularly and before each major revision to ensure that the Panel addresses all relevant published data. Medical subject headings and free text terms are combined to maximize retrieval of relevant citations from the PubMed, Scopus, EMBASE, and Web of Science databases. To be considered for inclusion, articles were required to have been published in English from 2010 to the present. Data from abstracts presented at national or international scientific conferences are also considered
|Rating of the evidence and RECOMMENDATIONS||The Guidance is presented in the form of RECOMMENDATIONS. Each RECOMMENDATION is rated in terms of the level of the evidence and strength of the recommendation, using a modification of the scale adapted from the American College of Cardiology and the American Heart Association Practice Guidelines (American Heart Association, 2014); (Shiffman, 2003). A summary of the supporting (and conflicting) evidence follows each RECOMMENDATION or set of RECOMMENDATIONS.|
|Data review and synthesis and preparation of RECOMMENDATIONS and supporting information||Draft RECOMMENDATIONS are developed by subgroups of the full Panel with interest and expertise in particular sections of the Guidance. Following development of supporting text and references, the sections are reviewed by the full Panel and Chairs. A penultimate draft is submitted to the AASLD and IDSA Governing Boards for final review and approval before posting online on the website, www.hcvguidelines.org.
Subgroups of the Panel meet regularly by conference call as needed to update RECOMMENDATIONS and supporting evidence. Updates may be prompted by new publications or presentations at major national or international scientific conferences, new drug approvals (or new indications, dosing formulations, or frequency of dosing), new safety warnings, or other information that may have a substantial impact on the clinical care of patients. Updates and changes in the Guidance are indicated by highlighted text on the online site and a notice of update is posted on the Home Page.
|Abbreviations||Commonly used abbreviations in the text with their expansions are listed in Methods Table 3.|
|Opportunity for Comments||Evidence-based comments may be submitted to the Panel by email to email@example.com, or by clicking on the “Send a comment to the Panel” button on www.hcvguidelines.org/contact-us. The Panel considers evidence-based comments about the RECOMMENDATIONS, ratings, and evidence summary but should not be contacted for individual patient management questions.|
Changes to this page made on November 28, 2016.